+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Erbitux"

Colorectal Cancer Therapeutics: Global Markets - Product Thumbnail Image

Colorectal Cancer Therapeutics: Global Markets

  • Report
  • March 2019
  • 124 Pages
  • Global
From
From
From
From
Colorectal Cancer KOL Interview - UK - Product Thumbnail Image

Colorectal Cancer KOL Interview - UK

  • Newsletter
  • May 2024
  • 14 Pages
  • United Kingdom
Colorectal Cancer KOL Interview - US, Northeast - Product Thumbnail Image

Colorectal Cancer KOL Interview - US, Northeast

  • Newsletter
  • May 2024
  • 14 Pages
  • United States
Colorectal Cancer Forecast and Market Analysis to 2036 - Product Thumbnail Image

Colorectal Cancer Forecast and Market Analysis to 2036

  • Report
  • September 2018
  • 630 Pages
  • Global
From
From
From
From
From
Erbitux- Drug Insight, 2019 - Product Thumbnail Image

Erbitux- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
Disease Analysis: Colorectal Cancer - Product Thumbnail Image

Disease Analysis: Colorectal Cancer

  • Report
  • May 2021
  • 88 Pages
  • Global
Portrazza - Product Thumbnail Image

Portrazza

  • Report
  • August 2018
  • 17 Pages
  • Global
From
From
From
Loading Indicator

Erbitux is a monoclonal antibody drug used to treat certain types of cancer, including lung cancer. It works by blocking the action of a protein called epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells. This helps to slow down or stop the growth of the cancer cells. Erbitux is usually used in combination with other chemotherapy drugs to treat advanced non-small cell lung cancer (NSCLC). It is also used to treat head and neck cancer, colorectal cancer, and other types of cancer. Erbitux is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and other types of cancer. It is available in both intravenous and oral formulations. The drug is marketed by Merck & Co. in the United States and by Bristol-Myers Squibb in Europe. Other companies involved in the Erbitux market include Amgen, AstraZeneca, and Eli Lilly. Show Less Read more